CBD and CBN show promise for better sleep without THC's side effects

Medical cannabis shows promise as an alternative treatment for insomnia, with a systematic review and meta-analysis finding that it may decrease sleep disturbance, reduce daytime sleepiness, and increase total sleep time. The research analyzed multiple cannabinoid formulations including CBD (cannabidiol), CBN (cannabinol), and THC (delta-9-tetrahydrocannabinol), administered through various routes such as oral capsules, oils, and sublingual solutions. Importantly, the findings suggest that medical cannabis has a favorable safety profile with only minor adverse effects when properly dosed and monitored, making it potentially attractive for the one-third of adults suffering from insomnia who may be seeking alternatives to traditional pharmaceuticals with their known side effects and limited long-term effectiveness.

The most effective dosing strategy identified in the research involves CBD doses of 50-300 mg and CBN doses of 20-100 mg, both showing safety and efficacy for sleep improvement. However, the analysis revealed an important nuance: lower CBD doses (less than 50 mg) required the addition of CBN to be effective. This combination approach opens new therapeutic possibilities for patients seeking optimized cannabinoid ratios. Notably, formulations containing THC did not demonstrate significant sleep improvements and were associated with higher rates of adverse effects, suggesting that insomnia patients should prioritize non-intoxicating cannabinoids instead.

Clinicians are advised to guide patients toward evidence-based self-care practices by recommending low-dose CBN or CBN/CBD combinations while avoiding THC entirely for insomnia treatment. The research emphasizes the importance of appropriate monitoring through sleep diaries, actigraphy, and validated assessment scales such as the Insomnia Severity Index, highlighting that successful medical cannabis use requires structured clinical guidance rather than unsupervised self-medication.